(Q35993027)

English

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial (English)

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

phase II clinical trial

0 references

phase III clinical trial

0 references

systemic lupus erythematosus

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

David A. Isenberg

9

object named as

David A Isenberg

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Caroline Gordon

8

object named as

Caroline Gordon

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

1

object named as

Joan T Merrill

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

7

object named as

Tammy O Utset

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

author name string

C Michael Neuwelt

2

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Daniel J Wallace

3

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Joseph C Shanahan

4

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Kevin M Latinis

5

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

James C Oates

6

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Hsin-Ju Hsieh

10

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

David Zhang

11

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Paul G Brunetta

12

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 January 2010

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Arthritis & Rheumatology

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

62

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

1

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

222-233

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

B-cell depletion for autoimmune thrombocytopenia and autoimmune hemolytic anemia in pediatric systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548300

2 October 2017

Effects of rituximab on resistant SLE disease including lung involvement.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548300

2 October 2017

Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548300

2 October 2017

Assessment of systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548300

2 October 2017

Dysfunctional B cells in systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548300

2 October 2017

Surviving the butterfly and the wolf: mortality trends in systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548300

2 October 2017

What have we learned from a 10-year experience with the LUMINA (Lupus in Minorities; Nature vs. nurture) cohort? Where are we heading?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548300

2 October 2017

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548300

2 October 2017

Diagnosis of systemic lupus erythematosus.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548300

2 October 2017

Pathogenesis of systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548300

2 October 2017

From BILAG to BLIPS--disease activity assessment in lupus past, present and future

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548300

2 October 2017

The role of B cells in lpr/lpr-induced autoimmunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548300

2 October 2017

Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548300

2 October 2017

Clinical significance of antibodies to double stranded DNA (dsDNA) for systemic lupus erythematosus (SLE).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548300

2 October 2017

The MOS 36-ltem Short-Form Health Survey (SF-36)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548300

2 October 2017

B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548300

11 July 2018

The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548300

11 July 2018

Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548300

11 July 2018

Systemic lupus erythematosus.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548300

23 September 2018

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548300

23 September 2018

Accrual of organ damage over time in patients with systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548300

23 September 2018

Systemic lupus erythematosus in three ethnic groups. XX. Damage as a predictor of further damage

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548300

23 September 2018

An open study of B lymphocyte depletion in systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548300

23 September 2018

A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548300

14 November 2018

The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: Measures of overall disease activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548300

14 November 2018

A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/20039413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

THE OCCURRENCE, NATURE AND DISTRIBUTION OF FLARES IN A COHORT OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A RHEUMATOLOGICAL VIEW

1 reference

https://pubmed.ncbi.nlm.nih.gov/20039413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/20039413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation

1 reference

https://pubmed.ncbi.nlm.nih.gov/20039413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/20039413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituximab-related late-onset neutropenia in a patient with severe rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20039413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network

1 reference

https://pubmed.ncbi.nlm.nih.gov/20039413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Depletion of B cells in murine lupus: efficacy and resistance

1 reference

https://pubmed.ncbi.nlm.nih.gov/20039413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prolonged B-cell depletion following rituximab therapy in systemic lupus erythematosus: a report of two cases

1 reference

https://pubmed.ncbi.nlm.nih.gov/20039413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus

1 reference

https://pubmed.ncbi.nlm.nih.gov/20039413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20039413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

SLICC/ACR Damage Index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus

1 reference

https://pubmed.ncbi.nlm.nih.gov/20039413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles

1 reference

https://pubmed.ncbi.nlm.nih.gov/20039413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Development of Autoantibodies before the Clinical Onset of Systemic Lupus Erythematosus

1 reference

https://pubmed.ncbi.nlm.nih.gov/20039413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Definition and treatment of lupus flares measured by the BILAG index

1 reference

https://pubmed.ncbi.nlm.nih.gov/20039413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity

1 reference

https://pubmed.ncbi.nlm.nih.gov/20039413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A longitudinal analysis of SLE patients treated with rituximab (anti-CD20): factors associated with B lymphocyte recovery

1 reference

https://pubmed.ncbi.nlm.nih.gov/20039413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neutropenia in patients treated with rituximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/20039413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone

1 reference

https://pubmed.ncbi.nlm.nih.gov/20039413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/ART.27233

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35993027&oldid=2108093561"